Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGIS-2: Ferric Maltol in Crohn's Disease
NCT01352221Phase 3Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Aug 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in iron deficiency anemia (IDA) comparing ST10 with Placebo (2 arms). Primary endpoint: Change in Haemoglobin Concentration From Baseline at 12 weeks. Started Aug 2011; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01352221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352221.